An observational study in Tardive Dyskinesia, sponsored by Power Life Sciences Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-23.
Sponsored by Power Life Sciences Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.
Among the 31 studies in Tardive Dyskinesia with a site in United States, this one is one of 3 that started in 2025, is one of 4 observational ones, and was the 28th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
Neurocrine Biosciences · Sites in United States, Bulgaria, Czechia and 3 more countries
Ages 18–75
Neurocrine Biosciences · Sites in United States
Ages 18+
iRxReminder · Sites in United States
Ages 18+
Corporal Michael J. Crescenz VA Medical Center · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 8
First in 1996; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 89 across the 27 interventional studies, 70 across the 3 observational. Of the 21 that completed or were terminated, 14 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Power Life Sciences Inc. is the lead sponsor of 111 studies on the registry; 109 are open to participants now.
Power Life Sciences Inc. has 1 study filed under Tardive Dyskinesia — fewer than ten, so there is no comparison to draw.
2 of the studies in Tardive Dyskinesia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365462Neurocrine BiosciencesEfficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | 2027-02 |
| NCT06997198University Hospitals Cleveland Medical CenterDeutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Tardive Dyskinesia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The statistical analysis of the collected data aims to reveal the many factors that influence patient involvement in clinical trials. Findings will be disseminated through conferences and scholarly papers to benefit all parties participating in clinical trials.
These findings will help to shape the design of future clinical trials for people with tardive dyskinesia, as well as enhance recruiting techniques and retention rates.
Tardive dyskinesia patients who are actively considering enrolling in a clinical trial for the said condition, but have not yet completed enrollment and randomization phases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rate of patients who decide to enroll in a tardive dyskinesia clinical research.
Time frame: 3 months
Number of tardive dyskinesia study participants who remain in clinical study until completion.
Time frame: 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Start is estimated for Feb 2025; primary completion for Feb 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.